FDA grants orphan drug status to H3 Biomedicine ’s cancer treatment H3B-8800

H3 Biomedicine, a member of Eisai ’s global Oncology Business Group, has received orphan drug designation from the US Food and Drug Administration (FDA) for its H3B-8800, a clinical compound used to treat patients with acute myelogenous leukaemia (AML…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news